From Complex Data Come Uncomplicated Products.

Our business is primarily focused in two areas. The first is searching the human genome for unique sets of genetic markers that are most typically associated with cancer and other chronic diseases.

The second is to use this information to create practical and efficient diagnostic tests, offered by local laboratories, that help physicians and caregivers make more informed decisions for patient care.

Breast Cancer eXagen™ is currently developing two breast cancer prognostic assays, eXagenBC™ for estrogen receptor/progesterone receptor positive (ER/PR+) patients and another test for ER/PR- patients. Both tests use fluorescent in situ hybridization (FISH) technology to assess the likelihood of breast cancer recurrence in women with newly diagnosed, early stage invasive ductal breast cancer. eXagenBC has been submitted for 510(k) clearance.

Other Cancers eXagen is developing an assay which is expected to be the first in vitro diagnostic test to detect genomic abnormalities occurring among the most common carcinomas affecting patients. eXagen employed its computational methods to discover genomic markers that will aid in the diagnosis of these cancers.

Gastroenterology eXagen is developing quantitative polymerase chain reaction (qPCR) assays that assess messenger ribonucleic acids (mRNAs) in peripheral blood mononuclear cells linked to inflammatory bowel disease. The eXagen test will assist health care providers in differentiating patients with inflammatory bowel disease from those with irritable bowel syndrome. A second diagnostic assay will help distinguish between Crohn's Disease and Ulcerative Colitis in patients with inflammatory bowel disease. The diagnosis of inflammatory bowel disease currently relies on a range of diagnostic procedures. New laboratory assays that can contribute to the diagnosis of inflammatory bowel disease will be of value.

Immune Response Up to four million people in the United States are infected with the Hepatitis C virus (HCV) and the number of infected people worldwide is approaching 200 million. Chronic HCV infection is a major public health problem, accounting for up to half of all cases of cirrhosis, end-stage liver disease and liver cancer. The standard regimen of interferon and ribavirin is costly and plagued by side effects. eXagen is developing two immune response tests for the Hepatitis C virus that will assist health care providers in identifing those patients most likely to respond to the standard treatment regimen.